Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Melanoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 13Gemcitabine 12Cyclophosphamide 10Carboplatin 10Specimen Handling 8Magnetic Resonance Spectroscopy 8Cisplatin 8Docetaxel 7X-Rays 6Filgrastim 6Doxorubicin 6Biopsy 6tislelizumab 5Radiosurgery 5Phantoms, Imaging 5Paclitaxel 5Nivolumab 5Irinotecan 5Bevacizumab 5130-nm albumin-bound paclitaxel 5spartalizumab 4palbociclib 4Thiotepa 4Temozolomide 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Mesna 4Ipilimumab 4Imatinib Mesylate 4Ifosfamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × resiquimod × Gastrointestinal × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡